# Depressive Disorder, Major FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/depressive-disorder-major

> 10 upcoming FDA catalysts in depressive Disorder, Major: seltorexant (JNJ) on Dec 2026 to Mar 2027 (topline data readout); seltorexant (JNJ) on December 2026 (primary completion); brenipatide (LLY) on February 2028 (primary completion); brenipatide (LLY) on Feb to May 2028 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 25, 2026 | [JNJ-89495120 primary completion](https://sec-api.dev/pdufa/jnj-89495120) | JNJ | Depressive Disorder, Major | completed | "NCT06785012 (A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06785012)) |
| Dec 2026 to Mar 2027 | [Seltorexant topline data readout](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559306)) |
| December 2026 | [Seltorexant primary completion](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559306)) |
| February 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07412756 (A Study of Brenipatide in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412756)) |
| Feb to May 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07412756 (A Study of Brenipatide in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412756)) |
| Aug to Nov 2028 | [Seltorexant topline data readout](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT07573176 (A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-24 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573176)) |
| August 2028 | [Seltorexant primary completion](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT07573176 (A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-24 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573176)) |
| December 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07775300 (A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775300)) |
| Dec 2028 to Mar 2029 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07775300 (A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775300)) |
| Sep to Dec 2029 | [Caplyta (lumateperone tosylate) topline data readout](https://sec-api.dev/pdufa/lumateperone) | JNJ | Depressive Disorder, Major | scheduled | "NCT07747389 (A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747389)) |
| September 2029 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Depressive Disorder, Major | scheduled | "NCT07747389 (A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747389)) |

## Drugs

- [JNJ-89495120](https://sec-api.dev/pdufa/jnj-89495120) (JNJ)
- [Seltorexant](https://sec-api.dev/pdufa/seltorexant) (JNJ)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Caplyta (lumateperone tosylate)](https://sec-api.dev/pdufa/lumateperone) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/depressive-disorder-major.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Depressive Disorder, Major FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/depressive-disorder-major

```bibtex
@misc{secapidev_indications_depressive_disorder_major_20261116,
  title        = {Depressive Disorder, Major FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/depressive-disorder-major}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_depressive_disorder_major_20261116","title":"Depressive Disorder, Major FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/depressive-disorder-major","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
